The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Abstract
The purpose of this review is to provide readers with guidance concerning treatment of patients with advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the context of clinical trial data. We discuss issues surrounding the treatment of patients with SCCHN, with an emphasis on recommendations based on results from phase II and III clinical trials published since 1980. Many options exist for the treatment of patients with SCCHN. The most important decisions involve determining which patients are in need of treatment and which are most likely to benefit from treatment. Although many chemotherapy treatments have been shown to induce responses, survival improvement remains an unfulfilled goal. Definitive data do not exist on the effects of chemotherapy on quality of life or progression-free survival as measures of clinical benefit in this setting. Performance status, history of prior treatment, extent of tumor, and need for palliation are the most important factors in the decision to treat a patient with chemotherapy for incurable SCCHN. Single-agent treatment with conventional doses of methotrexate remains a standard for most patients with advanced, recurrent or metastatic SCCHN. Cisplatin plus fluorouracil, cisplatin plus a taxane, and single-agent taxane are the most widely studied alternatives. There is a need for further trials with end points other than overall survival or tumor response in this patient population. Guidelines for patient selection and treatment options are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Denis, F., Garaud, P., Bardet, E., Alfonsi, M., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., & Calais, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.021 · Cited by 900
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Forastiere, A. A., Metch, B., Schuller, D. E., Ensley, J. F., Hutchins, L. F., Triozzi, P., Kish, J. A., McClure, S., VonFeldt, E., & Williamson, S. K. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1245 · Cited by 752
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Jacobs, C., Lyman, G., Velez-García, E., Sridhar, K. S., Knight, W., Hochster, H., Goodnough, L. T., Mortimer, J. E., Einhorn, L. H., & Schacter, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.257 · Cited by 628
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.057 · Cited by 496
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Green, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
Herbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Wong, S.-F. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.003 · Cited by 249
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Gligorov, J., & Lotz, J. P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_2-3 · Cited by 244
Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer
de Graeff, A., de Leeuw, J. R. J., Ros, W. J. G., Hordijk, G. J., Blijham, G. H., & Winnubst, J. A. M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00385-3 · Cited by 199 · cited 1×
“Additional predictors of poor outcome or shortened survival that should be considered when making treatment decisions include the presence of hypercalcemia and comorbidities such as poor cognitive function; ongoing heavy tobacco, alcohol, or other carcinogen use; and the absence of a strong social support system.(12-1…”
BackgroundForastiere, A. A., Leong, T., Rowinsky, E., Murphy, B. A., Vlock, D. R., DeConti, R. C., & Adams, G. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1088 · Cited by 159
CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck.
Wittes, R. E., Cvitkovic, E., Shah, J., Gerold, F. P., & Strong, E. W. (1977) · PubMed · Cited by 156
Olmi, P., Crispino, S., Fallai, C., Torri, V., Rossi, F., Bolner, A., Amichetti, M., Signor, M. A., Taino, R., Squadrelli, M., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03792-6 · Cited by 130
Eisenberger, M. A., Hornedo, J., Silva, H., Donehower, R. C., Spaulding, M. B., & Echo, D. V. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1506 · Cited by 125
Hong, W. K., Schaefer, S. D., Issell, B. F., Cummings, C., Luedke, D., Bromer, R. H., Fofonoff, S. A., D'Aoust, J. C., Shapshay, S. M., Welch, J., et al. (1983) · Cancer · Cited by 121
Guardiola, E., Peyrade, F., Chaigneau, L., Cupissol, D., Tchiknavorian, X., Bompas, E., Madroszyk, A.-C., Ronchin, P., Schneider, M., Bleuze, J. P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.05.019 · Cited by 119
Wirth, L. J., Haddad, R. I., Lindeman, N. I., Zhao, X., Lee, J. C., Joshi, V. A., Norris, C. M., & Posner, M. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4182 · Cited by 106
Browman, G. P., & Cronin, L. (1994) · PubMed · Cited by 101
Vokes, E. E., Cohen, E. E. W., Mauer, A. M., Karrison, T. G., Wong, S. J., Skoog-Sluman, L. J., Kozloff, M. F., Dancey, J. E., & Dekker, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.5504 · Cited by 91
Pivot, X. B., Raymond, É., Laguerre, B., Degardin, M., Cals, L., Armand, J., Lefebvre, J.-L., Gedouin, D., Ripoche, V., Kayitalire, L., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2010 · Cited by 88
Krug, L. M., Miller, V. A., Patel, J. D., Crapanzano, J. P., Azzoli, C. G., Gomez, J. E., Kris, M. G., Heelan, R. T., Pizzo, B., Tyson, L. B., et al. (2005) · Cancer · doi:10.1002/cncr.21428 · Cited by 84
Schornagel, J. H., Verweij, J., de Mulder, P. H. M., Cognetti, F., Vermorken, J. B., Cappelaere, P., Armand, J., Wildiers, J., de Graeff, A., & Clavel, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1649 · Cited by 78
Shin, D. M., Khuri, F. R., Glisson, B. S., Ginsberg, L. E., Papadimitrakopoulou, V., Clayman, G. L., Lee, J. J., Ang, K. K., Lippman, S. M., & Hong, W. K. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1316::aid-cncr1134>3.0.co;2-0 · Cited by 78
Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation.
Woods, R. L., Fox, R. M., & Tattersall, M. H. N. (1981) · BMJ · doi:10.1136/bmj.282.6264.600 · Cited by 71
The Impact of Comorbidity and Age on Survival with Laryngeal Cancer
Sabin, S. L., Rosenfeld, R. M., Sundaram, K., Har‐El, G., & Lucente, F. E. (1999) · Ear Nose & Throat Journal · doi:10.1177/014556139907800813 · Cited by 57
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck
Murphy, B. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.1.85 · Cited by 21
Colevas, A. D., Amrein, P. C., Gomolin, H. I., Barton, J. J., Read, R., Adak, S., Benner, S. E., Costello, R., & Posner, M. R. (2001) · Cancer · Cited by 18
Self-citationCaponigro, F., Rosati, G., Rosa, P. D., Avallone, A., Rosa, V. D., Lucia, L. D., Comella, P., & Comella, G. (2002) · Oncology · doi:10.1159/000065470 · Cited by 16
Moderate alcohol consumption and breast cancer risk
Chen, W. Y., Willett, W. C., ROSNER, B. A., & Coldtiz, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.515 · Cited by 8
Cited by
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,360
Self-citationHead and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.489 · Cited by 739
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0026 · Cited by 614
Self-citation
Metadata
- Authors
- Colevas, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-10
- Volume
- 24
- Issue
- 17
- Pages
- 2644-2652
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163802618
- Cited by
- 257
- References
- 38
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.